The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis
Abstract
Liver fibrosis is orchestrated by a complex network of signaling pathways regulating the deposition of extracellular matrix proteins during fibrogenesis. MicroRNAs (miRNAs) represent a family of small noncoding RNAs controlling translation and transcription of many genes. Recently, miRNAs have been suggested to crucially modulate cellular processes in the liver such as hepatocarcinogenesis. However, their role in liver fibrosis is not well understood. We systematically analyzed the regulation of miRNAs in a mouse model of carbon tetrachloride–induced hepatic fibrogenesis (CCl4) by gene array analysis, which revealed a panel of miRNA that were specifically regulated in livers of mice undergoing hepatic fibrosis. Within those, all three members of the miR-29-family were significantly down-regulated in livers of CCl4-treated mice as well as in mice that underwent bile duct ligation. Specific regulation of miR-29 members in murine fibrosis models correlated with lower expression of miR-29 in livers from patients with advanced liver fibrosis. Moreover, patients with advanced liver cirrhosis showed significantly lower levels of miR-29a in their serum when compared with healthy controls or patients with early fibrosis. On a cellular level, down-regulation of miR-29 in murine hepatic stellate cells (HSCs) was mediated by transforming growth factor beta (TGF-β) as well as inflammatory signals, namely, lipopolysaccharide (LPS) and nuclear factor kappa B (NF-κB). Furthermore, overexpression of miR-29b in murine HSC resulted in down-regulation of collagen expression. Conclusion: Our data indicate that miR-29 mediates the regulation of liver fibrosis and is part of a signaling nexus involving TGF-β- and NF-κB–dependent down-regulation of miR-29 family members in HSC with subsequent up-regulation of extracellular matrix genes. Thus they may represent targets for novel therapeutic strategies against hepatic fibrogenesis and also might evolve as biomarkers in the diagnosis of liver fibrosis. (Hepatology 2011.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The functions of animal microRNAs
Ambros, V. (2004) · Nature · doi:10.1038/nature02871 · Cited by 10,728
Circulating microRNAs as stable blood-based markers for cancer detection
Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804549105 · Cited by 7,969
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis
van Rooij, E., Sutherland, L. B., Thatcher, J. E., DiMaio, J. M., Naseem, R. H., Marshall, W. S., Hill, J. A., & Olson, E. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805038105 · Cited by 1,844
Phylogenetic Shadowing and Computational Identification of Human microRNA Genes
Berezikov, E., Guryev, V., van de Belt, J., Wienholds, E., Plasterk, R. H. A., & Cuppen, E. (2005) · Cell · doi:10.1016/j.cell.2004.12.031 · Cited by 1,270
Circulating microRNAs, potential biomarkers for drug-induced liver injury
Wang, K., Zhang, S., Marzolf, B., Troisch, P., Brightman, A., Hu, Z., Hood, L. E., & Galas, D. J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813371106 · Cited by 1,149
Gibbings, D. J., Ciaudo, C., Erhardt, M., & Voinnet, O. (2009) · Nature Cell Biology · doi:10.1038/ncb1929 · Cited by 991
MicroRNAs in the Human Heart: A Clue to Fetal Gene Reprogramming in Heart Failure
Thum, T., Galuppo, P., Wolf, C., Fiedler, J., Kneitz, S., van Laake, L. W., Doevendans, P. A., Mummery, C. L., Borlak, J., Haverich, A., et al. (2007) · Circulation · doi:10.1161/circulationaha.107.687947 · Cited by 888
mir-29 regulates Mcl-1 protein expression and apoptosis
Mott, J. L., Kobayashi, S., Bronk, S. F., & Gores, G. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210436 · Cited by 834
miR-221 overexpression contributes to liver tumorigenesis
Pineau, P., Volinia, S., McJunkin, K., Marchio, A., Battiston, C., Terris, B., Mazzaferro, V., Lowe, S. W., Croce, C. M., & Dejean, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907904107 · Cited by 699
Cited by
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches
Beermann, J., Piccoli, M.-T., Viereck, J., & Thum, T. (2016) · Physiological Reviews · doi:10.1152/physrev.00041.2015 · Cited by 1,726
NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinoma
Luedde, T., & Schwabe, R. F. (2011) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.213 · Cited by 1,345
Self-citationRecent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
Mechanisms of hepatic fibrogenesis
Lee, U. E., & Friedman, S. L. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.02.005 · Cited by 923
Pathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894
Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 759
Self-citationPathogenesis of liver cirrhosis
Zhou, W.-C. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7312 · Cited by 627
MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles
van Rooij, E., & Olson, E. N. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3864 · Cited by 624
TGF‐β signalling and liver disease
Fabregat, I., Moreno‐Càceres, J., Sánchez, A., Dooley, S., Dewidar, B., Giannelli, G., ten Dijke, P., & the IT‐LIVER Consortium (2016) · The FEBS Journal · doi:10.1111/febs.13665 · Cited by 600
Szabo, G., & Bala, S. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2013.87 · Cited by 588
TGF-β/Smad3 Signaling Promotes Renal Fibrosis by Inhibiting miR-29
Qin, W., Chung, A. C. K., Huang, X. R., Meng, X.-M., Hui, D. S. C., Yu, C.-M., Sung, J. J. Y., & Lan, H. Y. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010121308 · Cited by 566
The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury
Kriegel, A. J., Liu, Y., Fang, Y., Ding, X., & Liang, M. (2012) · Physiological Genomics · doi:10.1152/physiolgenomics.00141.2011 · Cited by 533
Suppression of microRNA-29 Expression by TGF-β1 Promotes Collagen Expression and Renal Fibrosis
Wang, B., Komers, R., Carew, R., Winbanks, C. E., Xu, B., Herman-Edelstein, M., Koh, P., Thomas, M., Jandeleit-Dahm, K., Gregorevic, P., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011010055 · Cited by 498
MicroRNAs as regulators, biomarkers and therapeutic targets in liver diseases
Wang, X., He, Y., Mackowiak, B., & Gao, B. (2021) · Gut · doi:10.1136/gutjnl-2020-322526 · Cited by 495
Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut
Seki, E., & Schnabl, B. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2011.219691 · Cited by 442
Exosomes as miRNA Carriers: Formation–Function–Future
Yu, X., Odenthal, M., & Fries, J. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122028 · Cited by 436
Mechanisms of liver fibrosis and its role in liver cancer
Dhar, D., Baglieri, J., Kisseleva, T., & Brenner, D. A. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370219898141 · Cited by 429
Smad3-Mediated Upregulation of miR-21 Promotes Renal Fibrosis
Zhong, X., Chung, A. C. K., Chen, H.-Y., Meng, X.-M., & Lan, H. Y. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111168 · Cited by 409
Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: An update
Elpek, G. Ö. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7260 · Cited by 382
Chou, J., Lin, J. H., Brenot, A., Kim, J.-W., Provot, S., & Werb, Z. (2013) · Nature Cell Biology · doi:10.1038/ncb2672 · Cited by 373
Apoptosis and Necrosis in the Liver
Guicciardi, M. E., Malhi, H., Mott, J. L., & Gores, G. J. (2013) · Comprehensive Physiology · doi:10.1002/cphy.c120020 · Cited by 353
The myofibroblast, a key cell in normal and pathological tissue repair
Darby, I. A., Zakuan, N., Billet, F., & Desmoulière, A. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-015-2110-0 · Cited by 328
Roncarati, R., Viviani Anselmi, C., Losi, M. A., Papa, L., Cavarretta, E., Da Costa Martins, P., Contaldi, C., Saccani Jotti, G., Franzone, A., Galastri, L., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.041 · Cited by 327
Pre-microRNA and Mature microRNA in Human Mitochondria
Barrey, E., Saint-Auret, G., Bonnamy, B., Damas, D., Boyer, O., & Gidrol, X. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020220 · Cited by 319
MicroRNAs in idiopathic pulmonary fibrosis
Pandit, K. V., Milosevic, J., & Kaminski, N. (2011) · Translational Research · doi:10.1016/j.trsl.2011.01.012 · Cited by 311
Inhibition of microRNA-29b reduces murine abdominal aortic aneurysm development
Maegdefessel, L., Azuma, J., Toh, R., Merk, D. R., Deng, A., Chin, J. T., Raaz, U., Schoelmerich, A. M., Raiesdana, A., Leeper, N. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61598 · Cited by 306
Recent advancement of molecular mechanisms of liver fibrosis
Seki, E., & Brenner, D. A. (2015) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.245 · Cited by 300
miR-29 Inhibits Bleomycin-induced Pulmonary Fibrosis in Mice
Xiao, J., Meng, X.-M., Huang, X. R., Chung, A. C., Feng, Y.-L., Hui, D. S., Yu, C.-M., Sung, J. J., & Lan, H. Y. (2012) · Molecular Therapy · doi:10.1038/mt.2012.36 · Cited by 293
Kumarswamy, R., Volkmann, I., Jazbutyte, V., Dangwal, S., Park, D.-H., & Thum, T. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.234286 · Cited by 293
Treating Disease at the RNA Level with Oligonucleotides
Levin, A. A. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1705346 · Cited by 287
The Progression of Liver Fibrosis Is Related with Overexpression of the miR-199 and 200 Families
Murakami, Y., Toyoda, H., Tanaka, M., Kuroda, M., Harada, Y., Matsuda, F., Tajima, A., Kosaka, N., Ochiya, T., & Shimotohno, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016081 · Cited by 282
Wang, X. W., Heegaard, N. H. H., & Ørum, H. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.007 · Cited by 280
Gallant-Behm, C. L., Piper, J., Lynch, J. M., Seto, A. G., Hong, S. J., Mustoe, T. A., Maari, C., Pestano, L. A., Dalby, C. M., Jackson, A. L., et al. (2019) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2018.11.007 · Cited by 278
Toll-Like Receptor 4 Signaling Augments Transforming Growth Factor-β Responses
Bhattacharyya, S., Kelley, K., Melichian, D. S., Tamaki, Z., Fang, F., Su, Y., Feng, G., Pope, R. M., Budinger, G. R. S., Mutlu, G. M., et al. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.09.007 · Cited by 264
Chen, L., Charrier, A., Zhou, Y., Chen, R., Yu, B., Agarwal, K., Tsukamoto, H., Lee, J. L., Paulaitis, M. E., & Brigstock, D. R. (2014) · Hepatology · doi:10.1002/hep.26768 · Cited by 264
A Systematic Review of miR-29 in Cancer
Kwon, J. J., Factora, T. D., Dey, S., & Kota, J. (2019) · Molecular Therapy Oncolytics · doi:10.1016/j.omto.2018.12.011 · Cited by 263
Ogawa, T., Enomoto, M., Fujii, H., Sekiya, Y., Yoshizato, K., Ikeda, K., & Kawada, N. (2012) · Gut · doi:10.1136/gutjnl-2011-300717 · Cited by 253
MicroRNA29: A Mechanistic Contributor and Potential Biomarker in Atrial Fibrillation
Dawson, K., Wakili, R., Ördög, B., Clauss, S., Chen, Y., Iwasaki, Y., Voigt, N., Qi, X. Y., Sinner, M. F., Dobrev, D., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.001207 · Cited by 252
Cellular mechanisms of tissue fibrosis. 5. Novel insights into liver fibrosis
Mallat, A., & Lotersztajn, S. (2013) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00230.2013 · Cited by 211
Spatial sorting enables comprehensive characterization of liver zonation
Ben-Moshe, S., Shapira, Y., Moor, A. E., Halpern, K. B., & Itzkovitz, S. (2019) · doi:10.1101/529784 · Cited by 205
Spatial sorting enables comprehensive characterization of liver zonation
Ben-Moshe, S., Shapira, Y., Moor, A. E., Manco, R., Veg, T., Bahar Halpern, K., & Itzkovitz, S. (2019) · Nature Metabolism · doi:10.1038/s42255-019-0109-9 · Cited by 205
Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis
Matsuda, M., & Seki, E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708876 · Cited by 189
miR-196a Downregulation Increases the Expression of Type I and III Collagens in Keloid Fibroblasts
Kashiyama, K., Mitsutake, N., Matsuse, M., Ogi, T., Saenko, V. A., Ujifuku, K., Utani, A., Hirano, A., & Yamashita, S. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.22 · Cited by 139
Pharmacological intervention in hepatic stellate cell activation and hepatic fibrosis
Schon, H.-T., Bartneck, M., Borkham-Kamphorst, E., Nattermann, J., Lammers, T., Tacke, F., & Weiskirchen, R. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00033 · Cited by 97
Self-citationHepatic Stellate Cells and Liver Fibrosis
Puche, J. E., Saiman, Y., & Friedman, S. L. (2013) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2013.tb00529.x · Cited by 89
Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells
Li, J., Zhang, Y., Kuruba, R., Gao, X., Gandhi, C. R., Xie, W., & Li, S. (2011) · Molecular Pharmacology · doi:10.1124/mol.110.068247 · Cited by 78
Wang, J., Wang, Y., Wang, Y., Ma, Y., Lan, Y., & Yang, X. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.444463 · Cited by 64
miR-1224 inhibits cell proliferation in acute liver failure by targeting the antiapoptotic gene Nfib
Roy, S., Bantel, H., Wandrer, F., Schneider, A. T., Gautheron, J., Vucur, M., Tacke, F., Trautwein, C., Luedde, T., & Roderburg, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.06.007 · Cited by 56
Self-citationMullenbrock, S., Liu, F., Szak, S., Hronowski, X., Gao, B., Juhasz, P., Sun, C., Liu, M., McLaughlin, H., Xiao, Q., et al. (2018) · Genes · doi:10.3390/genes9120588 · Cited by 35
Bibaki, E., Tsitoura, E., Vasarmidi, E., Margaritopoulos, G., Trachalaki, A., Koutoulaki, C., Georgopoulou, T., Spandidos, D., Tzanakis, N., & Antoniou, K. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8778 · Cited by 29
Yu, X., Elfimova, N., Müller, M., Bachurski, D., Koitzsch, U., Drebber, U., Mahabir, E., Hansen, H. P., Friedman, S. L., Klein, S., et al. (2022) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2022.02.013 · Cited by 27
Gomes, P. R., Graciano, M. F., Pantaleão, L. C., Rennó, A. L., Rodrigues, S. C., Velloso, L. A., Latorraca, M. Q., Carpinelli, A. R., Anhê, G. F., & Bordin, S. (2014) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00364.2013 · Cited by 27
Metadata
- Authors
- Roderburg, C., Urban, G.-W., Bettermann, K., Vucur, M., Zimmermann, H., Schmidt, S., Janssen, J., Koppe, C., Knolle, P., Castoldi, M., Tacke, F., Trautwein, C., & Luedde, T.
- Venue
- Hepatology
- Published
- 2011-01
- Volume
- 53
- Issue
- 1
- Pages
- 209-218
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2091096046
- Cited by
- 803
- References
- 26
- FWCI
- 30.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.